The effects of soy products and preparations on health issues of menopausal women in the light of randomized clinical studies (part 1);Wpływ produktów i preparatów z soi na problemy zdrowotne kobiet w okresie menopauzy w świetle randomizowanych badań klinicznych (cześć 1.)

Przeglad Menopauzalny

Volumn 4, Issue 3, 2005, Pages 15-24

  Kanadys, Wiesław M ^a  

^a Poradnia Ginekologiczno Połoznicza NZOZ Specjalistyka Czechów ^*  (Poland)

Author keywords

Isoflavones; Menopause; Randomized controlled trials; Soy

Indexed keywords

DAIDZEIN; ESTRADIOL; ESTROGEN; GENISTEIN; GESTAGEN; ISOFLAVONE DERIVATIVE; PHYTOESTROGEN; PLACEBO; SEX HORMONE; SOYBEAN PROTEIN;

ARTICLE; BODY WEIGHT DISORDER; BREAST CANCER; CEREBROVASCULAR ACCIDENT; CHOLELITHIASIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIET SUPPLEMENTATION; DIET THERAPY; DIETARY INTAKE; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HEALTH HAZARD; HEALTH STATUS; HIGH RISK PATIENT; HORMONAL THERAPY; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; LONG TERM CARE; MENOPAUSAL SYNDROME; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK REDUCTION; SOYBEAN; UTERUS CANCER; VAGINITIS; VENOUS THROMBOEMBOLISM; WEIGHT GAIN;

EID: 31544436035     PISSN: 16438876     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (75)

1. Nelson HD. Commonly used types of postmenopausal estrogen for treatment of hot flashes. Scientific review. JAMA 2004; 291: 1610-20.
2. Stachowiak G, Jedrzejczyk S, Połać I i wsp. Atrofia narzaów moczowo-płciowych u kobiet po menopauzie. Prz Menopauz 2003; 2 (5): 48-51.
3. Wells G, Tugwell P, Shea B, et al. Meta-analysis of therapies for postmenopausal osteoporosis. Endocr Rev 2002; 23: 529-39.
4. Hodis HN, Mack WJ, Lobo RA, et al. For the Estrogen in the Prevention of Atherosclerosis Trial Resaarch Group. Estrogen in the Prevention of atherosclerosis. Ann Intern Med 2001; 135: 939-53.
5. La Vecchia C, Brinton LA, McTiernan A. Menopause, hormone replacement therapy and cancer. Maturitas 2001; 39: 97-115.
6. Kanadys WM. Neurologiczne aspekty menopauzy - wpływ wdrożonej hormonalnej terapii zastepczej. I. Zaburzenia neurodegeneracyjne. Prz Menopauz 2003; 2 (3): 20-6.
7. Kanadys WM. Hormonalna terapia zastepcza - terapia ciagłych kontrowersji. Prz Menopauz 2004; 3 (2): 30-8.
8. Karakoc B, Erenus M. Compliance considerations with hormone replacement therapy. Menopause 1998; 5: 102-6.
9. Hulley S, Grady D, Bush T, et al. For the Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secundary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280: 605-13.
10. Grady D, Herrington D, Bittner V, et al. For the HERS Research Group. Cardiovascular disease outcomes during 6.8 years, of hormone therapy. Heart and Estrogen/progestin Replacement Study Follow-up (HERS II). JAMA 2002; 288: 49-57.
11. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33.
12. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women's Health Initiative randomized controlled trial. JAMA 2004; 291: 1701-12.
13. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362: 419-27.
14. Hersch AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and responses to recent evidence. JAMA 2004; 291: 47-53.
15. Wprowadzenie do Rekomendacji Zarzadu Głównego PTG w sprawie stosowania hormonalnej terapii zastepczej (Stan wiedzy na dzień 10.07.2004 r. - prof. dr hab. n. med. Tomasz Pertyński). Prz Menopauz 2004; 3 (4): 6-9.
16. Naftolin F, Schneider HP, Sturdee DW. Executive Committee of the International Menopause Society. Guidelines for the hormone treatment of women in the menopausal transition and beyand. Climacteric 2004; 7: 8-11.
17. Kass-Annese B. Alternative therapies for menopause. Clin Obstet Gynecol 2000; 43: 162-83.
18. Kronenberg F, Fugh-Berman A. Complementary and alternative medicine for menopausal symptoms: a review of randomized, controlled trials. Ann Intern Med 2002; 137: 805-13.
19. Boulet MJ, Oddens BJ, Lehert P, et al. Climacteric and menopause in seven southeast Asian countries. Maturitas 1994; 19: 157-76.
20. Ziegler RG, Hoover RN, Pike MC, et al. Migration patterns and breast cancer risk in Asian-American women. J Nat Cancer Inst 1993; 85: 1819-27.
21. Stanford JL, Herrinton LJ, Schwartz SM, Weiss NS. Breast cancer incidence in Asian migrants to the United States and their descendants. Epidemiology 1995; 6: 181-3.
22. Wang HJ, Murphy PA. Isoflavone composition of American and Japanese soybeans in Iowa: effects of variety, crop year, and location. J Agric Food Chem 1994; 42: 1674-7.
23. de Kleijn MJ, van der Schouw YT, Wilson PW, et al. Intake of dietary phytoestrogens is low in post-menopausal women in the United States: the Framingham study. J Nutr 2001; 131: 1826-32.
24. Setchell KD. Phytoestrogens: the biochemistry, physiology, and implications for human health of soy isoflavones. Am J Clin Nutr 1998; 68: 1333S-46S.
25. Duncan AM, Phipps WR, Kurzer MS. Phyto-oestrogens. Best Practice & Res Clin Endocrinol Metab 2003; 17: 253-71.
26. Watanabe S, Yamaguchi M, Sobue T, et al. Pharmacokinetics of soybean isoflavonoids in plasma, urine and feces of men after ingestion of 60 g baked soybean powder (kinako). J Nutr 1998; 128: 1710-5.
27. Adlercreutz H, Hockerstedt K, Bannwart C, et al. Effect of dietary components, including lignans and phytoestrogens, on enterohepatic circulation and liver metabolism of estrogens and on sex hormone binding globulin (SHBG). J Steroid Biochem 1987; 27: 1135-44.
28. Albertazzi P, Purdie DW. The nature and utility of the phytoestrogens: a review of the evidence. Maturitas 2002; 42: 173-85.
29. Kuiper GG, Carlson B, Grandien K, et al. Comparison at the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β. Endocrinology 1997; 138: 863-70.
30. Murkies AL, Wilcox G, Davis SR. Phytroestrogens. J Clin Endocrinol Metab 1998; 83: 297-303.
31. Markiewiez L, Garey J, Adlercreutz H, Guripide E. In vitro bioassays on nonsteroidal phytoestrogens. J Steroid Biochem Mol Biol 1993; 45: 399-405.
32. Migliaccio S, Anderson JJB. Isoflavones and skeletal health: are these molecules ready fo clinical application? Osteoporos Int 2003; 14: 361-8.
33. Arjmandi BH, Smith BJ. Soy isoflavones' osteoprotective role in postmenopausal women: mechanism of action. J Nutr Biochem 2002; 13: 130-7.
34. Anthony MS, Clarkson TB, Williams JK. Effects of soy isoflavones on atherosclerosis: potential mechanisms. Am J Clin Nutr 1998; 68 (suppl): 1390S-3S.
35. Wroblewski Lissin L, Cooke JP. Phytoestrogens and cardiovascular health. J Am Coll Cardiol 2000; 35: 1403-10.
36. Strauss L, Santti R, Saarinen N, et al. Dietary phytoestrogens and their role in hormonally dependent disease. Toxicol Lett 1998; 102-103: 349-54.
37. Mishra SI, Vivian Dickerson V, Najm W. Phytoestrogens and Breast Cancer Prevention: What is the Evidence? Am J Obstet Gynecol 2003; 188: S66-S70.
38. Murkies AL, Lombard C, Strauss BJ, et al. Dietary flour supplementation decreases post-menopausal hot flushes: effect of soy and wheat. Maturitas 1995; 21: 189-95.
39. Brzezinski A, Adlercreutz H, Shaoul R, et al. Short-term effects of phytoestrogen--rich diet on postmenopausal women. Menopause 1997; 4: 89-94.
40. Dalais FS, Rice GE, Wahlqvist ML, et al. Effects of dietary phytoestrogens in post-menopausal women. Climacteric 1998; 1: 124-9.
41. Albertazzi P, Pansini F, Bonaccorsi G, et al. The effect of dietary soy supplementation on hot flushes. Obstet Gynecol 1998; 91: 6-11.
42. Washburn S, Burke GL, Morgan T, Anthony M. Effect of soy protein supplementation on serum lipoproteins, blood pressure, and menopausal symptoms in perimenopausal women. Menopause 1999; 6: 7-13.
43. Quella SK, Loprinzi CL, Barton DL, et al. Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: a North Central Cancer Treatment Group Trial. J Clin Oncol 2000; 18: 1068-74.
44. Scambia G, Mango D, Signorile PG, et al. Clinical effects of a standardized soy extract in postmenopausal women: a pilot study. Menopause 2000; 7: 105-11.
45. Kotsopoulos D, Dalais FS, Liang YL, et al. The effects of soy protein containing phytoestrogens on menopausal symptoms in postmenopausal women. Climacteric 2000; 3: 161-7.
46. Upmalis DH, Lobo R, Bradley L, et al. Vasomotor symtom srelief by soy isoflavone extract tablets in postmenopausal women; a multicenter, double-blind, randomized, placebo-controlled study. Menopause 2000; 7: 236-42.
47. Germain AS, Peterson CT, Robinson JG, Aleker L. Isoflavone-rich or isoflavone-poor soy protein does not reduce menopausal symptoms during 24 weeks of treatment Menopause 2001; 8: 17-26.
48. Knight DC, Howes JB, Eden JA, Howes LG. Effects on menopausal symptoms and acceptability of isoflavone containing soy powder dietary supplementation. Climacteric 2001; 4: 13-8.
49. Han KK, Soares JM, Haidar MA, et al. Benefits of soy isoflavone therapeutic regimen on menopausal symptoms. Obstet Gynecol 2002; 99: 389-94.
50. Balk JL, Whiteside DA, Naus G, et al. A pilot study of the effects of phytoestrogens supplementation on postmenopausal endometrium. J Soc Gynecol Investig 2002; 9: 238-42.
51. Drapier Faure E, Chantre P, Mares P. Extract of a standardarized soy extract on hot flushes: a multicentre, double-blind, randomised, placebo-controlled study. Menopause 2002; 9: 329-34.
52. Van Patten CL, Olivotto IA, Chambers GK, et al. Effect of soy phytoestrogens on hot flashes in postmenopausal women with breast cancer: a randomized, controlled clinical trial. J Clin Oncol 2002; 20: 1449-55.
53. Sammartino A, Di Carlo C, Mandato AB, et al. Effects of genistein on the endometrium: ultrasonographic evaluation. Gynecol Endocrinol 2003; 17: 45-9.
54. Burke GL, Legault C, Anthony M, et al. Soy protein and isoflavone effects on vasomotor symptoms in peri- and postmenopausal women: the Soy Estrogen Alternative Study. Menopause 2003; 10: 147-53.
55. Penotti M, Fabio E, Modena AB, et al. Effect of soy-derived isoflavones on hot flushes, endometrial thickness, and the pulsatility index of the uterine and cerebral arteries. Fertil Steril 2003; 79: 1112-7.
56. Nikander E, Kilkkinen A, Metsa-Heikkila M, et al. A randomized placebo-controlled crossover trial with phytoestrogens in treatment of menopause in breast cancer patients. Obstet Gynecol 2003; 101: 1213-20.
57. Crisafulli A, Marini H, Bitto A, et al. Effects of genistein on hot flushes in early post-menopausal women: a randomized, double-blind EPT- and placebo-controlled study. Menopause. 2004; 11 (4): 400-4.
58. Nahas EP, Neto JN, De Luca L, et al. Benefits of soy germ isoflavones in postmenopausal women with contraindication for conventional hormone replacement therapy. Maturitas 2004, 48: 372-80.
59. Baird DD, Umbach DM, Lansdell L, et al. Dietary intervention study to assess estrogenicity dietary soy among postmenopausal women. J Clin Endocrinol Metab 1995; 80: 1685-95.
60. Chiechi LM, Putignano G, Guerra V, et al. The effect of a soy rich diet on the vaginal epithelium in postmenopause: a randomized double blind trial. Maturitas 2003; 45: 241-6.
61. Albertazzi P, Pansini F, Bottazzi M, et al. Dietary soy supplementation and phytoestrogen levels. Obstet Gynecol 1999; 94: 229-31.
62. Duncan AM, Underhill KEW, Xu X, et al. Modest hormonal effects of soy isoflavones in postmenopausal women. J Clin Endocrinol Metab 1999; 84: 3479-84.
63. Chiechi LM, Secreto G, Vimercati A, et al. The effects of a soy rich diet on serum lipids: the Menfis randomized trial. Maturitas 2002; 41: 97-104.
64. Unfer V, Casini ML, Costabile L, et al. Endometrial effects of long-term treatment with phytoestrogens: a randomized, double-blind, placebo-controlled study. Fertil Steril 2004; 82: 145-8.
65. Murray MJ, Meyer WR, Lessey BA, et al. Soy protein isolate with isoflavones does not prevent estradiol-induced endometrial hyperplasia in postmenopausal women: a pilot trial. Menopause 2003; 10: 456-64.
66. Lee HP, Gourley L, Duffy SW, et al. Dietary effects on breast-cancer risk in Singapore. Lancet 1991; 337: 1197-200.
67. Hirose K, Tajima K, Hamajima N, et al. A large-scale, hospital based case-control study of risk factors of breast cancer according to menopausal status. Jpn J Cancer Res 1995; 86: 146-54.
68. Wu AH, Ziegler RG, Horn-Ross PL, et al. Tofu and risk of breast cancer in Asian-American. Cancer Epidemiol Biomarkers Prev 1996; 5: 901-6.
69. Ingram D, Sanders K, Kolybaba M, et al. Case-control study of phyto-oestrogens and breast cancer. Lancet 1997; 350: 990-4.
70. Zheng W, Dai Q, Custer LJ, et al. Urinary excretion of isoflavonoids and the risk of breast cancer. Cancer Epidemiol Biomarkers Prev 1999; 8: 35-40.
71. Yuan JM, Wang QS, Ross RK, et al. Diet and breast cancer in Shanghai and Tianjin, China. Br J Cancer 1995; 71: 1353-8.
72. Key TJ, Sharp GB, Appleby PN, et al. Soya foods and breast cancer risk: a prospective study in Hiroshima and Nagasaki Japan. Brit J Cancer 1999; 81: 1248-56.
73. Keinan-Boker L, van Der Schouw YT, Grobbee DE, et al. Dietary phytoestrogens and breast cancer risk. Am J Clin Nutr 2004; 79: 282-8.
74. de Lemos ML. Effects of soy phytoestrogens genistein and daidzein on breast cancer growth. Ann Pharmacother 2001; 35: 1118-21.
75. de Lemos ML. Safety issues of soy phytoestrogens in breast cancer patient. J Clin Oncol 2002; 20: 3040-1.